Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
暂无分享,去创建一个
Robert Schmieder | A. Adjei | K. Ziegelbauer | D. Mumberg | J. Miner | F. Puehler | R. Neuhaus | M. Kissel | A. Scholz